HMOX1 and neoplasm: In this context, all the inhibitors already used in therapeutic schemes to block IDO, HO, ARGI and II, NOS2, PGE2, and TGF-β activity can be employed to reduce MSC influence on tumor cell growth (211–217) (Figure 3).